PEMBROLIZUMAB (alone or when added to a regimen above)

DRUG3 trials

Sponsors

University of California, Irvine, The University of Hong Kong, University of Florence

Conditions

Gastroesophageal AdenocarcinomaNasopharyngeal Cancer RecurrentNasopharyngeal Cancinoma (NPC)Peripheral Nerve DiseaseUrothelial Carcinoma (UC)

Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

RecruitingNCT05733689

University of California, IrvineGastroesophageal Adenocarcinoma

Start: 2025-06-27End: 2027-06-01Target: 20Updated: 2026-03-10

Phase 2

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Not yet recruitingNCT07129772

The University of Hong KongNasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)

Start: 2025-11-01End: 2028-06-30Target: 53Updated: 2025-09-04

Unknown Phase

Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)

Not yet recruitingNCT07629700

University of FlorencePeripheral Nerve Disease, Urothelial Carcinoma (UC)

Start: 2026-09-01End: 2028-09-01Target: 40Updated: 2026-06-08

Related Papers

Response adapted neoadjuvant therapy in gastric cancer (RANT-GC): A phase Ib feasibility trial.

Journal of Clinical Oncology2026-01-10